VANCOUVER, British Columbia--(BUSINESS WIRE)--Aug 2, 2018--Zymeworks Inc. (NYSE/TSX: ZYME), a clinical-stage biopharmaceutical company developing multifunctional biotherapeutics, today announced that management will present at the upcoming Canaccord Genuity 38th Annual Growth Conference taking place August 8-9, 2018 in Boston, MA, USA.

The Company will provide a corporate update and present upcoming catalysts on Wednesday, August 8, 2018 at 2:00 p.m. ET. Interested parties can access a live webcast of the presentation via a link from Zymeworks’ website at http://ir.zymeworks.com/events-and-presentations, which will also host a recorded replay available afterwards.

About Zymeworks Inc.

Zymeworks is a clinical-stage biopharmaceutical company dedicated to the discovery, development, and commercialization of next-generation multifunctional biotherapeutics. Zymeworks’ suite of complementary therapeutic platforms and its fully-integrated drug development engine provide the flexibility and compatibility to precisely engineer and develop highly-differentiated product candidates. Zymeworks’ lead product candidate, ZW25, is a novel bispecific antibody currently being evaluated in an adaptive Phase 1 clinical trial. Zymeworks is also advancing a deep pipeline of preclinical product candidates and discovery-stage programs in immuno-oncology and other therapeutic areas. In addition to Zymeworks’ wholly-owned pipeline, its therapeutic platforms have been further leveraged through multiple strategic partnerships with global biopharmaceutical companies.

View source version on businesswire.com:https://www.businesswire.com/news/home/20180802005135/en/

CONTACT: Zymeworks Inc.

Investor Inquiries:

Ryan Dercho, Ph.D., 604-678-1388

ir@zymeworks.com

or

Media Inquiries:

Angela Bitting, 925-202-6211

a.bitting@comcast.net

KEYWORD: UNITED STATES NORTH AMERICA CANADA MASSACHUSETTS

INDUSTRY KEYWORD: HEALTH BIOTECHNOLOGY CLINICAL TRIALS MEDICAL DEVICES PHARMACEUTICAL MEDICAL SUPPLIES

SOURCE: Zymeworks Inc.

Copyright Business Wire 2018.

PUB: 08/02/2018 08:00 AM/DISC: 08/02/2018 08:01 AM

http://www.businesswire.com/news/home/20180802005135/en